A Phase 1C, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 300 mg of SQ109 Given Once Daily for 14 Days in Normal, Healthy Male and Female Volunteers

Trial Profile

A Phase 1C, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 300 mg of SQ109 Given Once Daily for 14 Days in Normal, Healthy Male and Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2013

At a glance

  • Drugs SQ 109 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 24 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top